146-150 the impact of patient assistance programs and the 340b drug pricing program on medication cost

American Journal of Managed Care

Volumn 20, Issue 2, 2014, Pages 146-150

  Castellon, Yelba M ^a,b   Bazargan Hejazi, Shahrzad ^a,b   Masatsugu, Miles ^c   Contreras, Roberto ^c  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c East Valley Community Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CODING; DISEASE REGISTRY; HEALTH CARE SYSTEM; HOSPITAL CARE; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MANAGED CARE ORGANIZATION; OUTPATIENT CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK; COST CONTROL; COST OF ILLNESS; DRUG COST; FEMALE; LEGISLATION AND JURISPRUDENCE; MALE; MEDICAL CARE; MEDICALLY UNINSURED; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

COST OF ILLNESS; COST SAVINGS; DRUG COSTS; FEMALE; HUMANS; MALE; MEDICAL ASSISTANCE; MEDICALLY UNINSURED; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84897424276     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. De Geest S, Sabaté E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003;2(4):323. (Pubitemid 37518223)
2. Kitchman M, Neuman T, Sandman D, et al. Seniors and prescription drugs: findings from a 2001 survey of seniors in eight states. Menlo, CA: Henry J. Kaiser Family Foundation; 2002.
3. Stuart B, Grana J. Ability to pay and the decision to medicate. Med Care. 1998;36(2):202-211. (Pubitemid 128454310)
4. Schafheutle EI. The impact of prescription charges on asthma patients is uneven and unpredictable: Evidence from qualitative interviews. Prim Care Respir J. 2009;18(4):266-272.
5. Tseng CW, Brook RH, Keeler E, Steers WN, Mangione CM. Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292(8):952-960. (Pubitemid 39097205)
6. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4):421-429. (Pubitemid 32097260)
7. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse: do patients with chronic illnesses tell their doctors? Arch Intern Med. 2004;164(16):1749-1755. (Pubitemid 39215643)
8. Schafheutle EI, Hassell K, Noyce PR, Weiss MC. Access to medicines: cost as an influence on the views and behaviour of patients. Health Soc Care Community. 2002;10(3):187-195. (Pubitemid 36844273)
9. Kennedy J, Tuleu I, Mackay K. Unfilled prescriptions of Medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J Manag Care Pharm. 2008;14(6):553-560.
10. Werling K, Abraham S, Strelec J. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations. Health Care Law Mon. 2007:3-12.
11. Barlas S. The 340B Discount Drug Program at Ozarks Medical Center: an economic stimulus plan for Missouri. P T. 2011;36(5):280-281.
12. Bright DR, Adams AJ, Akala FO, Lengel AJ, Martin SJ, Powers MF. Implementation of a $4 generic drug program in a 340B pharmacy. Am J Health Syst Pharm. 2010;67(11):929-931.
13. Harmon GN, Lefante J, Roy W, et al. Outpatient medication assistance program in a rural setting. Am J Health Syst Pharm. 2004;61(6): 603-607. (Pubitemid 38901749)
14. Mounts VL, Ringenberg DG, Rhees K, Partridge C. Implementation of a patient medication assistance program in a community pharmacy setting. J Am Pharm Assoc (2003). 2005;45(1):76-81.
15. Coleman CI, Reddy P, Quercia RA, Gousse G. Cost-benefit analysis of a pharmacy-managed medication assistance program for hospitalized indigent patients. Am J Health Syst Pharm. 2003; 60(4):378-382. (Pubitemid 36749039)
16. Weiner S, Dischler J, Horvitz C. Beyond pharmaceutical manufacturer assistance: broadening the scope of an indigent drug program. Am J Health Syst Pharm. 2001;58(2):146-150. (Pubitemid 32098703)
17. Duke KS, Raube K, Lipton HL. Patient-assistance programs: assessment of and use by safety-net clinics. Am J Health Syst Pharm. 2005;62(7):726-731. (Pubitemid 40462842)
18. Petrarca AM, Lengel AJ, Powers MF. Comparison of patient assistance program software. Am J Health Syst Pharm. 2011;68(14): 1331-1338.
19. Keough CL, Webster SA. 340B program presents opportunities - and challenges. Healthc Financ Manage. 2009;63(11):42-44, 46, 48.
20. Radford A, Slifkin R, Schur C, Cheung K, Baernholdt M. Rural hospitals: are you missing out on drug savings? Healthc Financ Manag. 2008; 62(6):82-85.
21. Young D. Persistent problems plague 340B program. Am J Health Syst Pharm. 2006;63(1):8, 10, 12.
22. Clifton GD, Byer H, Heaton K, Haberman DJ, Gill H. Provision of pharmacy services to underserved populations via remote dispensing and two-way videoconferencing. Am J Health Syst Pharm. 2003; 60(24):2577-2582. (Pubitemid 44712859)
23. Felder TM, Palmer NR, Lal LS, Mullen PD. What is the evidence for pharmaceutical patient assistance programs? a systematic review. J Health Care Poor Underserved. 2011;22(1):24-49.